Published in Cancer Immunol Immunother on March 04, 2003
Have we overestimated the benefit of human(ized) antibodies? MAbs (2010) 1.05
Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer (2011) 1.04
Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J Cancer (2011) 0.87
Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects. Biologics (2007) 0.84
Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity. MAbs (2015) 0.84
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol (2015) 0.75
Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma. PLoS One (2016) 0.75
Generation and in vivo characterization of a chimeric αvβ5-targeting antibody 14C5 and its derivatives. EJNMMI Res (2013) 0.75
Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. Clin Cancer Res (2003) 1.13
Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother (2006) 0.94
Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy. Clin Cancer Res (2003) 0.87
Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma. J Nucl Med (2007) 0.87
Characterization of human IgG antimouse antibody in patients with B-cell malignancies. Clin Cancer Res (2003) 0.85
Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies. Clin Cancer Res (2005) 0.82
Constitutive expression of proinflammatory complement components by subsets of neurons in the central nervous system. J Neuroimmunol (2002) 0.81
Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma. Int J Oncol (2007) 0.79
Documentation of idiotypic cascade after Lym-1 radioimmunotherapy in a patient with non-Hodgkin's lymphoma: basis for extended survival? Clin Cancer Res (2003) 0.77